ストックスクリーナーアプリを入手
12.58
4.14%
-0.53
前日終値:
$13.11
開ける：
$13.03
24時間の取引高:
241.26K
Relative Volume:
0.27
時価総額：
$900.13M
収益：
$133.62M
当期純損益:
$-177.37M
株価収益率:
-4.3529
EPS:
-2.89
ネットキャッシュフロー:
$23.50M
1週間 パフォーマンス:
-1.74%
1か月 パフォーマンス:
-18.76%
6か月 パフォーマンス:
+31.32%
1年 パフォーマンス:
-38.58%
1日の値動き範囲:
$12.51
$13.22
1週間の範囲:
$12.41
$13.74
52週間の値動き範囲:
$6.92
$20.46
Xencor Inc Stock (XNCR) Company Profile
XNCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.61 | 936.19M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.62 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.90 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.06 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-10-29 | アップグレード | Barclays | Underweight → Overweight |
| 2025-09-17 | 再開されました | Barclays | Underweight |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2024-12-12 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 繰り返されました | BTIG Research | Buy |
| 2024-02-28 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 開始されました | BofA Securities | Buy |
| 2022-12-06 | 開始されました | Cowen | Outperform |
| 2022-10-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-21 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-02-24 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2020-02-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-01-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-08-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-04-12 | 開始されました | Guggenheim | Buy |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2017-03-02 | 開始されました | Instinet | Neutral |
| 2017-03-02 | 繰り返されました | Wedbush | Outperform |
| 2016-10-04 | 開始されました | Piper Jaffray | Overweight |
| 2015-12-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-05 | 繰り返されました | MLV & Co | Buy |
| 2015-02-12 | 繰り返されました | Oppenheimer | Outperform |
| 2015-01-28 | 繰り返されました | MLV & Co | Buy |
| 2014-07-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Xencor Inc (XNCR) 最新ニュース
Activity Recap: Is Xencor Inc impacted by rising ratesQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative? - Yahoo Finance
Market Catalysts: What is the target price for Xencor Inc stockMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SG Americas Securities LLC Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones - Yahoo Finance
Navigating the Valuation Gap in Xencor Shares - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Down 7.1%Here's Why - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – Time to Sell? - Defense World
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Merger Talk: What hedge fund activity signals for Xencor Inc stockJuly 2025 Action & Accurate Intraday Trade Tips - Bộ Nội Vụ
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving AverageTime to Sell? - MarketBeat
Performance Recap: Can Xencor Inc stock outperform in a bear marketMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Weekly Earnings: Is Xencor Inc a top pick in the sector2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
ImmunityBio, Xencor Drugs Win E.U. Nods - labusinessjournal.com
Xencor's Clinical Milestone Paves Way for Potential Revaluation () - aktiencheck.de
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Xencor, Inc.Common Stock (NQ: XNCR - FinancialContent
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs By Investing.com - Investing.com Nigeria
IPO Launch: Will Xencor Inc stock reach Wall Street targetsWeekly Trade Summary & Daily Momentum Trading Reports - Bộ Nội Vụ
Xencor, Inc. (XNCR) Stock Analysis: Biotech Innovator With Over 100% Potential Upside - DirectorsTalk Interviews
Will Xencor Inc. stock benefit from upcoming earnings reports2025 Price Targets & Weekly Return Optimization Alerts - Улправда
How Xencor Inc. stock reacts to Fed rate cuts2025 Top Decliners & High Accuracy Investment Entry Signals - Улправда
Will Xencor Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Consensus Trade Alerts - Улправда
Is Xencor Inc. stock in correction or buying zoneQuarterly Profit Summary & AI Based Trade Execution Alerts - ulpravda.ru
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - BioSpace
Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028 - marketscreener.com
Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028 - TradingView — Track All Markets
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs - Investing.com
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Star TribuneXencor, Inc.Common Stock (Nasdaq:XNCR) Stock Quote - FinancialContent
Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy - MSN
Xencor (NASDAQ:XNCR) Trading Down 7.1%Time to Sell? - MarketBeat
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Xencor SVP Desjarlais sells $1.15 million in shares - Investing.com
With Xencor Stock Sliding, Have You Assessed The Risk? - Trefis
What drives Xencor Inc stock priceMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Xencor Inc (XNCR) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.05%
大文字化:
|
ボリューム (24 時間):